A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults
Authors:
Open Access
- 5 February 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 22 (8) , 1814-1826
Abstract
To evaluate the analgesic potential, safety, tolerability, and pharmacokinetics of VX-150, a pro-drug of a highly selective NaV1.8 inhibitor, in healthy subjects. This was a randomized, double-blind, placebo-controlled, crossover study in healthy subjects. Twenty healthy male subjects with an age of 18–55 years, inclusive, were enrolled. Eligibility was based on general fitness, absence of current or previous medical conditions that could compromise subject safety, and a training assessment of pain tolerance across pain tests to exclude highly tolerant individuals whose tolerance could compromise the ability to detect analgesic responses. All dosed subjects completed the study. Subjects were randomized 1:1 to one of two sequences receiving a single VX-150 dose and subsequently placebo, or vice versa, with at least 7 days between dosing. A battery of pain tests (pressure, electrical stair, [capsaicin-induced] heat, and cold pressor) was administered before dosing and repetitively up to 10 h after dosing, with blood sampling up to 24 h after dosing. Safety was monitored throughout the study. Data were analyzed with a repeated-measures mixed-effects model. VX-150 induced analgesia in a variety of evoked pain tests, without affecting subject safety. Significant effects were reported for the cold pressor and heat pain thresholds. Maximum median concentration for the active moiety was 4.30 µg/mL at 4 h after dosing. Results of this proof-of-mechanism study are supportive of the potential of VX-150, a highly selective NaV1.8 channel inhibitor, to treat various pain indications.Keywords
Funding Information
- Vertex Pharmaceuticals
This publication has 58 references indexed in Scilit:
- The G1662S NaV1.8 mutation in small fibre neuropathy: impaired inactivation underlying DRG neuron hyperexcitabilityJournal of Neurology, Neurosurgery & Psychiatry, 2013
- Small-Fiber Neuropathy Nav1.8 Mutation Shifts Activation to Hyperpolarized Potentials and Increases Excitability of Dorsal Root Ganglion NeuronsJournal of Neuroscience, 2013
- A review of topical high‐concentration L‐menthol as a translational model of cold allodynia and hyperalgesiaEuropean journal of pain, 2013
- Gain-of-function Na v 1.8 mutations in painful neuropathyProceedings of the National Academy of Sciences, 2012
- Involvement of Nav 1.8 sodium ion channels in the transduction of mechanical pain in a rodent model of osteoarthritisArthritis Research & Therapy, 2012
- TRPM8 and Nav1.8 sodium channels are required for transthyretin-induced calcium influx in growth cones of small-diameter TrkA-positive sensory neuronsMolecular Neurodegeneration, 2011
- Experimental muscle pain impairs descending inhibitionPain, 2008
- Ethnic Differences in Diffuse Noxious Inhibitory ControlsThe Journal of Pain, 2008
- A-803467, a potent and selective Na v 1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the ratProceedings of the National Academy of Sciences, 2007
- Multiple sodium channels and their roles in electrogenesis within dorsal root ganglion neuronsThe Journal of Physiology, 2007